Was everyone wrong about fish oil? Is venture capital a cartel? And what’s with all those ketamine clinics?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a recap of the news that shocked biotech: A prescription-grade fish oil significantly reduced the risks of heart attacks and strokes. Then we talk to STAT’s Megan Thielking about her investigation into the rapid rise — and considerable risks — of clinics offering ketamine as an off-label treatment for depression. And biotech entrepreneur Ethan Perlstein joins us to talk about the flaws he sees in biotech’s venture capital model. Finally, there’s a lightning round, exploring identical migraine drugs, impoverished pharma CEOs, and why hedge fund managers can’t get enough of drug stocks.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].